PLx Pharma Inc. (PLXP)
After hours:
| Previous Close | 2.3400 |
| Open | 2.3200 |
| Bid | 2.3700 x 3200 |
| Ask | 2.4700 x 900 |
| Day's Range | 2.2800 - 2.4500 |
| 52 Week Range | 1.8100 - 21.5000 |
| Volume | |
| Avg. Volume | 189,351 |
| Market Cap | 66.089M |
| Beta (5Y Monthly) | 4.44 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.1020 |
| Earnings Date | Mar 10, 2022 - Mar 14, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 16.33 |
- GlobeNewswire
PLx Pharma Inc. to Present at JMP Securities 2022 Life Sciences Conference on June 15, 2022
SPARTA, N.J., June 01, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. The Company, with its lead products VAZALORE 81 mg and VAZALORE 325 mg liquid-filled aspirin capsules (ref
- GlobeNewswire
PLx Pharma Inc. Showcases VAZALORE at The Annual Meeting of The Society for Cardiovascular Angiography and Interventions
VAZALORE Featured in Prominent Publication as Promising Alternative to Current Aspirin Options for Secondary Prevention of Cardiac EventsSPARTA, N. J., May 20, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury
- Zacks
PLx Pharma, Inc. (PLXP) Reports Q1 Loss, Lags Revenue Estimates
PLx Pharma, Inc. (PLXP) delivered earnings and revenue surprises of 4.35% and 11.36%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
